{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:35:52Z","timestamp":1784183752264,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.eplepsyres.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,2,11]],"date-time":"2018-02-11T10:13:30Z","timestamp":1518344010000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Pharmacokinetic variability of valproate during pregnancy \u2013 Implications for the use of therapeutic drug monitoring"],"prefix":"10.1016","volume":"141","author":[{"given":"Cecilie","family":"Johannessen Landmark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette Huuse","family":"Farmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margrete Larsen","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arton","family":"Baftiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten I.","family":"Lossius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2018.02.004_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1528-1167.2008.01964.x","article-title":"Italian consensus conference on epilepsy and pregnancy, labor and puerperium","volume":"50","author":"Aguglia","year":"2009","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2018.02.004_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8 and UGT1A10","volume":"37","author":"Argikar","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.eplepsyres.2018.02.004_bib0015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.eplepsyres.2018.02.004_bib0020","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/epi.12302","article-title":"Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry","volume":"54","author":"Battino","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.eplepsyres.2018.02.004_bib0025","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","article-title":"Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate","volume":"87","author":"Bromley","year":"2016","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.eplepsyres.2018.02.004_bib0030","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eplepsyres.2018.02.004_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JCP.0000000000000087","article-title":"Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring","volume":"34","author":"Deligiannidis","year":"2014","journal-title":"J. Clin. Psychopharmcol."},{"key":"10.1016\/j.eplepsyres.2018.02.004_bib0040","series-title":"PRAC Recommends Strengthening the Restrictions on the Use of Valproate in Women and Girls","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.eplepsyres.2018.02.004_bib0045","unstructured":"European Medicines Agency New review of valproate use in pregnancy and women of childbearing age. (Accessed 13TH March 20170 at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Valproate_and_related_substances\/human_referral_prac_000066.jsp&mid=WC0b01ac05805c516f."},{"key":"10.1016\/j.eplepsyres.2018.02.004_bib0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.seizure.2015.02.026","article-title":"Intrauterine growth retardation in foetuses of women with epilepsy","volume":"28","author":"Farmen","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.02.004_bib0055","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00002826-198512000-00007","article-title":"Free level monitoring of carbamazepine and valproic acid: clinical significance","volume":"8","author":"Froscher","year":"1985","journal-title":"Clin. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2018.02.004_bib0060","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","article-title":"Host factors affecting antiepileptic drug delivery-pharmacokinetic variability","volume":"64","author":"Johannessen Landmark","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.02.004_bib0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine and topiramate-a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.02.004_bib0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies of antiepileptic drugs \u2013 from one dose to individualisation of treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Johannessen Landmark","year":"2016","journal-title":"Epileptic Disord."},{"issue":"10","key":"10.1016\/j.eplepsyres.2018.02.004_bib0075","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1111\/epi.13872","article-title":"Pharmacokinetic variability of valproate in women of childbearing","volume":"58","author":"Johannessen Landmark","year":"2017","journal-title":"Epilepsia"},{"issue":"3A","key":"10.1016\/j.eplepsyres.2018.02.004_bib0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF01962699","article-title":"Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn","volume":"14","author":"Johannessen","year":"1992","journal-title":"Pharm. Weekbl. Sci."},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.02.004_bib0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5507\/bp.2015.055","article-title":"Serum levels of valproic acid during delivery in mothers and in umbilical cord \u2013 correlation with birth length and weight","volume":"159","author":"Kacirova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.eplepsyres.2018.02.004_bib0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00007691-198905000-00002","article-title":"Valproic acid disposition and protein binding in pregnancy","volume":"11","author":"Koerner","year":"1989","journal-title":"Ther. Drug Monit."},{"issue":"9566","key":"10.1016\/j.eplepsyres.2018.02.004_bib0095","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblended randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eplepsyres.2018.02.004_bib0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.yebeh.2009.04.026","article-title":"Antiepileptic drug use in women of childbearing age","volume":"15","author":"Meador","year":"2009","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0110","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/epi.13802","article-title":"Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations","volume":"58","author":"Patsalos","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.02.004_bib0115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2165\/00003088-198207040-00004","article-title":"Plasma protein binding of drugs in pregnancy","volume":"7","author":"Perucca","year":"1982","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0120","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/epi.13029","article-title":"Valproate still has a place in women with epilepsy","volume":"56","author":"Perucca","year":"2015","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0125","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic drug monitoring of lacosamide in Norway: pharmacokinetic variability, clinical efficacy and tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem. Res."},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2018.02.004_bib0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"issue":"19","key":"10.1016\/j.eplepsyres.2018.02.004_bib0140","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0145","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"et al: valproate in the treatment of epilepsy in women and girls: recommendations from a joint task Force of ILAE-commission on European Affairs and European Academy of Neurology (EAN)","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.eplepsyres.2018.02.004_bib0150","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/epi.13437","article-title":"Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP","volume":"57","author":"Tomson","year":"2016","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.02.004_bib0155","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.13036","article-title":"Commentary valproate in the treatment of epilepsy in women and girls: the need for recommendations","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"2 Suppl. 5","key":"10.1016\/j.eplepsyres.2018.02.004_bib0160","first-page":"12","article-title":"Antiepileptic drug disposition during pregnancy","volume":"42","author":"Yerby","year":"1992","journal-title":"Neurology"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118300123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118300123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:38:06Z","timestamp":1760276286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118300123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"alternative-id":["S0920121118300123"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.02.004","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic variability of valproate during pregnancy \u2013 Implications for the use of therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}